1
|
Sedhom R, Beshai R, Moussa P, Megaly M, Mohsen A, Abramov D, Stoletniy L, Elgendy IY. Outcomes With Malignancy-Associated High-Risk Pulmonary Embolism: A Nationwide Analysis. Mayo Clin Proc 2024; 99:81-89. [PMID: 37632484 DOI: 10.1016/j.mayocp.2023.03.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/23/2022] [Revised: 02/21/2023] [Accepted: 03/01/2023] [Indexed: 08/28/2023]
Abstract
OBJECTIVE To examine the characteristics and outcomes among patients with high-risk pulmonary embolism (PE) and malignancy. PATIENTS AND METHODS The Nationwide Readmissions Database was used to identify hospitalizations with high-risk PE from January 1, 2016, to December 31, 2019. The main outcome was the difference in all-cause in-hospital mortality. RESULTS Among 28,547 weighted hospitalizations with high-risk PE, 4,825 (16.9%) had malignancy. Admissions with malignancy had a lower prevalence of other comorbid conditions except for anemia and coagulopathy. The use of systemic thrombolysis, catheter-directed interventions, and surgical embolectomy was less common among admissions with malignancy, whereas the use of inferior vena cava filter was more common among those with malignancy. All-cause in-hospital mortality was higher among admissions with malignancy even after adjustment (adjusted odds ratio, 1.91; 95% CI, 1.72 to 2.11; P<.001). Metastatic genitourinary, gastrointestinal (other than colorectal), and lung malignancies were associated with the highest incidence of in-hospital mortality. The incidence of intracranial hemorrhage (3.9% vs 3.1%; P=.056) and the composite of non-intracranial hemorrhage bleeding (21.9% vs 20.6%; P=.185) was not different between admissions with and without malignancy. However, admissions with malignancy had higher incidence of gastrointestinal bleeding. CONCLUSION In this nationwide analysis of patients admitted with high-risk PE, malignancy was independently associated with an increased risk of in-hospital mortality. The risk was highest among patients with metastatic genitourinary, gastrointestinal, and lung malignancies. Advanced therapies were less frequently used among patients with malignancy.
Collapse
Affiliation(s)
- Ramy Sedhom
- Division of Cardiology, Loma Linda University Medical Center, Loma Linda, CA, USA
| | - Rafail Beshai
- Division of Internal Medicine, Jefferson Health, Washington Township, NJ, USA
| | - Peter Moussa
- Division of Hematology and Oncology, UC San Diego, La Jolla, CA, USA
| | - Michael Megaly
- Division of Cardiology, Henry Ford Hospital, Detroit, MI, USA
| | - Amr Mohsen
- Division of Cardiology, Loma Linda University Medical Center, Loma Linda, CA, USA
| | - Dmitry Abramov
- Division of Cardiology, Loma Linda University Medical Center, Loma Linda, CA, USA
| | - Liset Stoletniy
- Division of Cardiology, Loma Linda University Medical Center, Loma Linda, CA, USA
| | - Islam Y Elgendy
- Division of Cardiovascular Medicine, Gill Heart Institute, University of Kentucky, Lexington, KY, USA.
| |
Collapse
|
2
|
Gonzales-Viera OA, Sánchez-Sarmiento AM, Fernandes NCCDA, Guerra JM, Ressio RA, Catão-Dias JL. Fatal haemorrhage and neoplastic thrombosis in a captive African lion (Panthera leo) with metastatic testicular sex cord-stromal tumour. Acta Vet Scand 2017; 59:69. [PMID: 29029632 PMCID: PMC5640962 DOI: 10.1186/s13028-017-0337-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2017] [Accepted: 10/08/2017] [Indexed: 11/10/2022] Open
Abstract
BACKGROUND The study of neoplasia in wildlife species contributes to the understanding of cancer biology, management practices, and comparative pathology. Higher frequencies of neoplasms among captive non-domestic felids have been reported most commonly in aging individuals. However, testicular tumours have rarely been reported. This report describes a metastatic testicular sex cord-stromal tumour leading to fatal haemorrhage and thrombosis in a captive African lion (Panthera leo). CASE PRESENTATION During necropsy of a 16-year-old male African lion, the left testicle and spermatic cord were found to be intra-abdominal (cryptorchid), semi-hard and grossly enlarged with multiple pale-yellow masses. Encapsulated haemorrhage was present in the retroperitoneum around the kidneys. Neoplastic thrombosis was found at the renal veins opening into the caudal vena cava. Metastases were observed in the lungs and mediastinal lymph nodes. Histology revealed a poorly differentiated pleomorphic neoplasm comprised of round to polygonal cells and scattered spindle cells with eosinophilic cytoplasm. An immunohistochemistry panel of inhibin-α, Ki-67, human placental alkaline phosphatase, cytokeratin AE1/AE3, cKit, vimentin and S100 was conducted. Positive cytoplasmic immunolabeling was obtained for vimentin and S100. CONCLUSIONS The gross, microscopic and immunohistochemical findings of the neoplasm were compatible with a poorly differentiated pleomorphic sex cord-stromal tumour. Cause of death was hypovolemic shock from extensive retroperitoneal haemorrhage and neoplastic thrombosis may have contributed to the fatal outcome. To our knowledge, this is the first report of sex cord-stromal tumour in non-domestic felids.
Collapse
|
3
|
Brenner B, Hoffman R, Balashov D, Shutluko E, Culić SD, Nizamoutdinova E. Control of Bleeding Caused by Thrombocytopenia Associated With Hematologic Malignancy: An Audit of the Clinical Use of Recombinant Activated Factor VII. Clin Appl Thromb Hemost 2016; 11:401-10. [PMID: 16244765 DOI: 10.1177/107602960501100406] [Citation(s) in RCA: 28] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
This paper presents an analysis of 24 cases in which recombinant factor VIIa (rFVIIa) was used in the management of hemorrhage in patients with thrombocytopenia associated with hematologic malignancies. This is the largest case aggregation to date and focuses on preliminary experience in the off-label use of this hemostatic agent. Data were extracted from the international, Internet-based registry, www.haemostasis.com, accessed in September 2003. The search results were manually cross-checked against monthly summary reports. The physicians providing the cases were contacted individually to approve the use of their cases, supply any information missing from the database, and validate the data already held. Patients with acute myeloid leukemia, acute lymphoblastic leukemia, Hodgkin’s disease, non-Hodgkin’s lymphoma, Burkitt’s lymphoma, B-cell or T-cell lymphoma, or aplastic anemia received rFVIIa at total doses of between 18 and 1040 μg/kg body weight. Bleeding stopped in 11 of 24 (46%) patients, markedly decreased in 8 of 24 (33%) patients, and decreased in 4 of 24 (17%) patients. In most patients, the response was achieved within 2.5 hours of administration of rFVIIa. The use of rFVIIa was generally well tolerated—1 case of ischemic stroke was considered to be possibly related to rFVIIa administration, but this has yet to be confirmed. A review of these 24 cases submitted to the www.haemostasis.com database suggests that rFVIIa is beneficial in the management of hemorrhage in patients with thrombocytopenia and hematologic malignancies. This warrants further investigation in rigorously controlled clinical trials.
Collapse
Affiliation(s)
- Benjamin Brenner
- Thrombosis and Hemostasis Unit, Department of Hematology and Bone Marrow Transplantation, Rambam Medical Center, Haifa, Israel.
| | | | | | | | | | | |
Collapse
|
4
|
Cardim N, Toste J, Carvalho V, Nunes I, Ferreira D, Carmelo V, Oliveira ASN, Ferro J, Mariana S, Almeida A, Machado FP, Roquette J. Playing games with a thrombus: a dangerous match. Paradoxical embolism from a huge central venous cathether thrombus: a case report. Cardiovasc Ultrasound 2010; 8:6. [PMID: 20233431 PMCID: PMC2850880 DOI: 10.1186/1476-7120-8-6] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/16/2010] [Accepted: 03/16/2010] [Indexed: 11/10/2022] Open
Abstract
Thromboembolism is a major cause of death in cancer patients. The association between paraneoplastic hypercoagulability of oncological patients and long-term central venous catheters (CVC) may result in CVC associated thrombosis. Patent Foramen Ovale (PFO), especially when associated with atrial septal aneurysm (ASA) is a risk factor for paradoxical embolism. We report a case of paradoxical embolism with stroke in an oncological patient with a huge CVC thrombus playing "ping-pong" with an hypermobile ASA with a PFO. We review the management of hypercoagulability in oncologic patients and discuss the potential role of routine transthoracic echocardiography before the implantation of long term central venous catheters to identify predisposing conditions to paradoxical embolism and select patients for anticoagulant therapy.
Collapse
Affiliation(s)
- Nuno Cardim
- Cardiology Department, Hospital da Luz. Av. Lusíada, 100. 1500-650 Lisbon, Portugal
| | - Júlia Toste
- Cardiology Department, Hospital da Luz. Av. Lusíada, 100. 1500-650 Lisbon, Portugal
| | - Vanessa Carvalho
- Cardiology Department, Hospital da Luz. Av. Lusíada, 100. 1500-650 Lisbon, Portugal
| | - Igor Nunes
- Cardiology Department, Hospital da Luz. Av. Lusíada, 100. 1500-650 Lisbon, Portugal
| | - Daniel Ferreira
- Cardiology Department, Hospital da Luz. Av. Lusíada, 100. 1500-650 Lisbon, Portugal
| | - Vanda Carmelo
- Cardiology Department, Hospital da Luz. Av. Lusíada, 100. 1500-650 Lisbon, Portugal
| | - Ana SN Oliveira
- Neurology Department, Hospital da Luz. Av. Lusíada, 100. 1500-650 Lisbon, Portugal
| | - José Ferro
- Neurology Department, Hospital da Luz. Av. Lusíada, 100. 1500-650 Lisbon, Portugal
| | - Sylvie Mariana
- Cardiology Department, Hospital da Luz. Av. Lusíada, 100. 1500-650 Lisbon, Portugal
| | - Adelaide Almeida
- Cardiology Department, Hospital da Luz. Av. Lusíada, 100. 1500-650 Lisbon, Portugal
| | - Francisco P Machado
- Cardiology Department, Hospital da Luz. Av. Lusíada, 100. 1500-650 Lisbon, Portugal
| | - José Roquette
- Cardiology Department, Hospital da Luz. Av. Lusíada, 100. 1500-650 Lisbon, Portugal
| |
Collapse
|
5
|
Abstract
Patients with solid and hematologic malignancies presenting with major bleeding or thrombotic complications, potentially life-ending events in a cancer patient's clinical course, usually require admission to an intensive care unit (ICU), making their diagnosis and management even more important for the intensivist. Given the significant advances in the diagnosis and treatment of almost all types of cancers in recent years, the intensivist is likely to encounter an ever-increasing number of cancer patients in the ICU setting with these complications. Abnormal hemostasis can occur as a consequence of both the pathology and treatment of cancer. Because cancer can have multiple effects on hemostatic equilibrium, treatment of these complications can be more complex than in the general population. This article reviews the physiology of coagulation and fibrinolysis, with special attention to those aspects that are most frequently altered in the setting of malignancy. The pathophysiology of bleeding and thrombotic complications specific to critically ill cancer patients are then detailed, and the diagnostic and therapeutic strategies are discussed. Special emphasis is placed on new cancer medications that have an effect on hemostasis, and on novel clotting and anticoagulant agents that are available to the intensivist for the management of these patients.
Collapse
Affiliation(s)
- Karen S Carlson
- Department of Medicine, New York Presbyterian Hospital of Weill Cornell Medical College, 525 E 68th Street, Payson 3, New York, NY 10065, USA
| | | |
Collapse
|
6
|
Pastores SM, Voigt LP. Acute respiratory failure in the patient with cancer: diagnostic and management strategies. Crit Care Clin 2010; 26:21-40. [PMID: 19944274 DOI: 10.1016/j.ccc.2009.10.001] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
Abstract
Acute respiratory failure (ARF) remains the major reason for admission to the intensive care unit (ICU) in patients with cancer and is often associated with high mortality, especially in those who require mechanical ventilation. The diagnosis and management of ARF in patients who have cancer pose unique challenges to the intensivist. This article reviews the most common causes of ARF in patients with cancer and discusses recent advances in the diagnostic and management approaches of these disorders. Timely diagnosis and treatment of reversible causes of respiratory failure, including earlier use of noninvasive ventilation and judicious ventilator and fluid management in patients with acute lung injury, are essential to achieve an optimal outcome. Close collaboration between oncologists and intensivists helps ensure that clear goals, including direction of treatment and quality of life, are established for every patient with cancer who requires mechanical ventilation for ARF.
Collapse
Affiliation(s)
- Stephen M Pastores
- Department of Anesthesiology and Critical Care Medicine, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue C1179, New York, NY 10065, USA.
| | | |
Collapse
|
7
|
Schmid S, Friesenecker B, Lorenz I, Innerhofer P, Koscielny J, Velik-Salchner C, Mutz N, Fries D. Administration of recombinant activated factor VII (NovoSeven) in three cases of uncontrolled bleeding caused by disseminated intravascular coagulopathy. Clin Appl Thromb Hemost 2007; 13:313-7. [PMID: 17636194 DOI: 10.1177/1076029607302567] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Recombinant activated factor VII has been used successfully in many cases of traumatic and surgical bleeding complications that were unresponsive to standard treatment. However, because disseminated intravascular coagulation can develop from a thrombin burst as a side effect of recombinant activated factor VII, it is not yet established for bleeding complications induced by disseminated intravascular coagulation. This article presents 3 patients with severe sepsis and fulminant disseminated intravascular coagulation. Excessive microvascular bleeding persisted despite conventional therapy, and surgical intervention and radiologic embolization did not control bleeding. After administration of recombinant activated factor VII, bleeding ceased in all patients, and no overt thromboembolic events occurred. One patient survived to be discharged from the hospital. The other 2 patients died from refractory multiorgan failure and overall poor prognosis. Recombinant factor VIIa might be an option for the treatment of severe bleeding complications in the case of DIC refractory to the conventional therapy.
Collapse
Affiliation(s)
- Stefan Schmid
- Department of General and Surgical Critical Care Medicine, Innsbruck Medical University, Austria
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Aissaoui Y, Benkabbou A, Alilou M, Moussaoui R, El Hijri A, Abouqal R, Azzouzi A, Slaoui A. La thrombopénie en réanimation chirurgicale: incidence, analyse des facteurs de risque et impact sur le pronostic. Presse Med 2007; 36:43-9. [PMID: 17261447 DOI: 10.1016/j.lpm.2006.05.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/29/2005] [Accepted: 05/12/2006] [Indexed: 11/23/2022] Open
Abstract
OBJECTIVE To determine the incidence of thrombocytopenia in a surgical intensive care unit (ICU), the risk factors associated with it, and its effect on patient outcome. METHODS During a 6-month period, all patients admitted to the surgical intensive care unit were studied prospectively. The factors associated with thrombocytopenia were evaluated by univariate and multivariate analysis. RESULTS The study included 112 patients with a mean age of 50+/-18 years and a mean SAPS II (Simplified Acute Physiology Score) of 25+/-19: 41 developed thrombocytopenia (incidence=36,6%). Risk factors associated with it in the univariate analysis were high SAPS II, high organ dysfunction score, invasive intravascular catheters, sepsis, septic shock, and bleeding. After multivariate logistic regression analysis, only 3 independent risk factors remained for thrombocytopenia: bleeding (OR=11.9; 95% CI: 3.3-43.6; p<0.001), sepsis (OR=4.1; 95% CI: 1.3-11.7; p=0.013) and SAPS II>20 (OR=2.8; 95% CI: 1.0-7.8; p=0.042). Although mortality was higher in patients with than without thrombocytopenia , this difference was not statistically significant (41% versus 31%, p=0.26). Survival was similar in both groups, according to the Kaplan-Meier survival curve. CONCLUSION Thrombocytopenia is common in surgical ICUs. Bleeding and sepsis are the major risk factors. In this study, thrombocytopenia was not an independent factor of poor vital outcome in these critically ill patients.
Collapse
Affiliation(s)
- Younès Aissaoui
- Service de Réanimation Chirurgicale, Hôpital Avicenne, CHU Ibn Sina, Rabat, Maroc.
| | | | | | | | | | | | | | | |
Collapse
|
9
|
Affiliation(s)
- Brett A Miles
- Division of Oral and Maxillofacial Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75216, USA
| | | |
Collapse
|
10
|
Abstract
Heparin, and particularly low molecular weight heparin, is widely used for the treatment of patients with deep vein thrombosis (DVT) and the prevention of DVT that commonly accompanies malignancy. Malignant growth has also been linked experimentally to the function of heparin-like glycosaminoglycans (HLGAGs). In addition to the voluminous general literature on this subject, the heparin-cancer link has been the theme of at least three entire journal issues in recent months. These include the June 15, 2001 issue of Thrombosis Research, the November 2001 Supplement to Haemostasis, and the February 2002 issue of Seminars in Thrombosis and Hemostasis. Previous reviews have documented the historical development of this link that includes evidence from basic biochemistry and cell biology, studies in experimental animal model systems, and clinical trials. This concise review updates recent basic and clinical data on the heparin-cancer link that clarify mechanisms by which HLGAGs regulate the malignant behavior of cells. Electronic access to information that is increasing geometrically has become indispensable. Evidence for control of tumor cell growth by heparin-binding growth factors, tumor cell invasion by heparin-inhibitable enzyme systems, tumor cell metastasis by heparin-binding cell surface selectins, tumor angiogenesis, and tumor matrix formation related to deposition of fibrinogen/fibrin provides a secure theoretical foundation for systematic testing of this class of compounds in patients with cancer. HLGAGs may be a fundamental intermediate in the abnormal growth regulation characteristic of neoplasia that is susceptible to targeted intervention.
Collapse
Affiliation(s)
- Leo R Zacharski
- The Department of Veterans Affairs Medical Center, White River Jct., Vermont 05009, USA.
| | | |
Collapse
|